The Latest
-
Permission granted by Gilead Sciences
Deep DiveGilead could potentially end HIV. But will it be able to?
After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.
-
Scott Olson via Getty Images
Lilly’s manufacturing bet; hints of a biotech revival
Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.
-
Getty Images
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.
-
Getty Images
As Chinese biotechs recognize their value, the bargain era may be over
Rising average upfront payments signal that buyers see value in Chinese assets.
-
Getty Images
Q&AVC sees early signs of a biotech market spring as long winter fades
The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.
-
Getty Images
Federal court blocks RFK Jr.’s moves to upend US vaccine policy
HHS ignored established protocols in altering the childhood immunization schedule and overhauling a CDC panel, according to the ruling.
-
Permission granted by Bayer
What’s at stake for Bayer in its Supreme Court showdown?
A key case being heard by the Supreme Court could help the large pharma put its Roundup litigation to rest.
-
Courtesy of Novo Nordisk
Novo regained weight loss footing in the pill arena — but Lilly is coming
Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?
-
Alamy
Keytruda’s reign continues; pharma’s megadeal drought
Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.
-
Getty Images
New FDA guidance could elevate pharma’s biosimilar market
Biologic copycats are making a bigger impact on drug prices as U.S. regulators open the doors wider, and new guidance could improve their standing even more.
-
Permission granted by Merck & Co.
Keytruda and Padcev could become cancer’s power couple
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
-
Getty Images
Servier’s $2.5B cancer bet underlines a quick oncology growth strategy
Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.
-
Getty Images
Executives want in, but researchers want out — how pharma’s US job picture is changing
While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.
-
Alamy
The first KRAS drugs have been sluggish on the market. Will the next generation fare better?
The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.
-
Permission granted by Bavarian Nordic
Biopharma’s recent string of CEO splits
Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.
-
Permission granted by Exact Sciences
Q&ACancer tests are becoming more precise and guiding pharma R&D
Abbott’s major takeover of Exact Sciences showcases a rising push to leverage cancer tests in precision oncology therapy and R&D.
-
Paul Morigi / Getty Images via Getty Images
Inside the race to thwart the dramatic rise in early-onset colorectal cancer
The increasingly common disease still presents a major challenge in oncology.
-
Sarah Silbiger via Getty Images
What 3 recent FDA rejections reveal about shifts inside the agency
The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.
-
Getty Images
J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
Spravato became a blockbuster despite ketamine’s dangerous abuse history, causing doctors to balance the real-world implications of its use.
-
Getty Images
Big Pharma’s next entrant could come from China
Companies with a growing international presence like Jiangsu Hengrui Pharmaceuticals are on their way to joining the big leagues.
-
Rebecca Pifer/PharmaVoice
How PBM reforms could push drugmakers into the pricing spotlight
The Consolidated Appropriations Act's landmark PBM overhaul removes financial incentives tied to pharma list prices, potentially leaving drugmakers to defend their own practices.
-
Getty Images
Biohaven says FDA roadblocks leave rare disease patients in limbo
An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.
-
Getty Images
China’s biopharma advance draws financial investment
Experts are still keeping a close eye on geopolitical uncertainties, but licensing deals are turning into monetary growth.
-
Getty Images
Will the FDA yank mRNA vaccines?
Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.
-
Getty Images
How does the FDA really feel about psychedelics? We could soon find out.
Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.
